Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

WTI and Brent crude rose to about $91.01 and $95.63 per barrel, respectively, as escalating U.S.-Iran tensions around the Strait of Hormuz added to inflation risk; the 10-year Treasury yield held near 4.818%, its highest level since November 2023. August nonfarm payrolls rose 162,000 versus 53,000 expected, with June and July revised up by a combined 55,000, reducing the urgency for Federal Reserve rate cuts despite softer JOLTS openings and a 38,000 ADP gain. Major U.S. equity indexes gained modestly during the week, but elevated oil prices, yields and a widening $88.6 billion July trade deficit reinforce a cautious macro outlook.

Analysis

The investable signal is not a broad risk-off event but a higher-for-longer real-rate and energy-input regime that widens dispersion. Consumer-credit lenders such as OPRT face a double hit: elevated warehouse/securitization funding costs and a greater probability that lower-income borrowers absorb fuel-price pressure through higher delinquencies; this can rapidly impair both earnings estimates and funding-market confidence. Conversely, LNG has relatively limited direct sensitivity to domestic oil prices, but a sustained geopolitical risk premium can improve the value of flexible U.S. liquefaction capacity and strengthen long-dated contracting appetite.

Within the listed names, PLTR and HIMS are most exposed to multiple compression if the discount-rate reset persists, even if operating execution remains intact; high-expectation equities need accelerating revisions to offset a rising equity-risk premium. FDS is a cleaner defensive relative-value expression: recurring data revenue, high incremental margins, and low commodity exposure should make its earnings stream more valuable than cyclical or consumer-credit alternatives, though its valuation limits outright upside. TMO and DGX offer healthcare defensiveness, but TMO remains more sensitive to biotech funding conditions and instrument-order cyclicality than DGX.

The consensus risk is treating resilient payroll data as unambiguously bullish. The more important implication is a delayed easing cycle while energy raises headline inflation, creating a 1-3 month headwind for long-duration equities and leveraged consumers before any material slowdown is visible in headline employment. This thesis is falsified by a prompt de-escalation that drives crude materially lower, or by a meaningful decline in inflation expectations and the 10-year yield without deterioration in credit spreads; either would reopen the duration trade.

Key Decisions for Investors

• Initiate a 1-3 month pair: long FDS / short OPRT, sized dollar-neutral. The pair isolates resilient recurring revenue from consumer-credit and funding-cost exposure; target 10-15% relative return, with exit if OPRT delinquency guidance improves or if the 10-year yield falls below 4.4%.
• Maintain or add LNG on pullbacks rather than chase spot-energy beta. Use a 6-12 month horizon and target 15-20% upside from improved contract optionality and geopolitical scarcity premium; reduce if European/Asian gas spreads compress materially or announced liquefaction volumes face execution delays.
• Hedge high-multiple software exposure through PLTR put spreads dated 2-4 months, preferably financed against existing long exposure rather than as a standalone short. The payoff is attractive if yields remain elevated through the next inflation and policy cycle; close the hedge on a sustained break lower in real yields or a material upward revision to PLTR revenue guidance.
• Avoid adding OPRT until quarterly net charge-offs, funding spreads, and provision guidance demonstrate that fuel and borrowing-cost pressure is not migrating into the loan book. A positive revision in those metrics is the required trigger for reassessment, not recent share-price momentum.
• For a lower-beta defensive sleeve, prefer DGX over TMO for the next quarter: DGX has less sensitivity to capital-equipment budgets and biotech financing. Reverse the preference if TMO reports a clear acceleration in bioprocess and instrument orders, which would overwhelm the macro-duration headwind.